Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 31, Issue 1, 2000, Pages 60-62

  Goldstein, Franz ^a,b   DiMarino Jr , Anthony J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

5 aminosalicylate; Diarrhea; Inflammatory bowel disease; Mesalamine

Indexed keywords

MESALAZINE;

ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DIARRHEA; ENTERITIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIARRHEA; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED;

EID: 0033922379     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200007000-00014     Document Type: Article

References (17)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety ot sulphasalazine. Lancet 1977;2:892-5.
2. Van Hees PAM, Baker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21:632-5.
3. Gaginella TS, Walsh RE. Sulfasalazine: multiplicity of action. Dig Dis Sci 1992;37:801-12.
4. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
5. Marteau P, Nelet F, LeLu M, Deavaux C. Adverse events in patients treated with aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949-56.
6. rd ed. Montvale. NJ: Medical Economics Company: 1999.
7. Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Int Med 1990;112:50-60.
8. Peppercorn MA. Update on the aminosalicylates. A promise fulfilled [editorial]. Gastroenterology 1988;95:1677-83.
9. Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol 1991;86: 460-3.
10. Svartz N. Salazopyrin, a new sulfanilamide preparation: B. therapeutic results in ulcerative colitis. Acta Med Seaml 1942;110:557-90.
11. Goldstein F, Murdock MG. Clinical and radiologic improvement of regional enteritis and enterocolitis after treattnent with salicylazosulfapyridine. Am J Dig Dis 1991;16:421-31.
12. Taffet ST, Das KM, Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983;28:833-42.
13. Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity and related new drug development. Ann Intern Med 1984;101:377-86.
14. Kornbluth A, Sachar DB. Ulcerative colitis guidelines in adults. Am J Gastroenterol 1997;92:204-11.
15. Robinson M. Optimizing therapy in inflammatory bowel disease. Am J Gastroenterol 1997;92(suppl):12S-7S.
16. Hanauer SB, Myers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997;92:559-66.
17. Spiro HM. The power of hope. A doctor's perspective. New Haven CT: Yale University Press. 1998.